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for 1 to 5 years in a US Medicare Health Maintenance Organi-
zation. The study population was identiﬁed using ICD-9 codes
(332;332.0) for PD and a claim for at least one ﬁlled PD pre-
scription identiﬁed using NDC codes. Medication Possession
Ratio (MPR) was estimated as proxy for adherence to PD med-
ications, with a threshold of 0.80 indicating adherence. PD
symptom progression was deﬁned as increase in prescription
strength, addition of another PD medication, an emergency room
visit or hospitalization related to PD. Demographic, clinical, and
economic variables were extracted from the dataset. Prevalence
of non-adherence was calculated over all years and for each year
of eligibility. Logistic regression was used to assess relation
between medication adherence and PD symptom progression.
Sensitivity analyses were conducted for MPR scores less than 0.6,
0.4, and 0.2. RESULTS: The study population (N = 470 patient-
years) had mean MPR score of 0.49 (±0.38). An average of 66%
of study population was not adherent to their PD medications
(MPR < 0.8 implies non-adherence). Sensitivity analysis with
MPR scores less than 0.6, 0.4, and 0.2 indicated an average of
56%, 46% and 35% were not adherent to their PD medications
respectively. Subjects adherent to their PD medications (MPR >=
0.8) had 67% less odds of experiencing PD symptom progres-
sion (OR = 0.33; CI:0.12–0.85) compared to people not adher-
ent to PD medications. All subjects with MPR < 0.2 experienced
PD symptom progression. CONCLUSION: High prevalence of
non-adherence to PD medication and its association with PD
symptom progression, irrespective of MPR threshold chosen,
indicates it is a signiﬁcant problem. There is a need for mecha-
nisms to improve medication adherence in PD, namely improved
patient understanding, simpliﬁed treatment regimens and
improved tolerability proﬁles.
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OBJECTIVES: Over-utilization of emergency department (ED)
services for non-urgent medical conditions has been noted as a
problem for decades. Headache is the sixth most common reason
for ED visits. This study examined factors of ED use in a
migraine population. METHODS: Medical and Rx claims of
Georgia Medicaid beneﬁciaries who had at least one migraine
medical claim (ICD-9 of 346.xx) or one triptan/ergot claim
between Jan 2002 and Dec 2005, and were continuously eligi-
ble from 6 months before to 12 months after ﬁrst migraine claim
were analyzed. Subjects who had a narcotic claim and a medical
claim for cancer (ICD-9 140–239), fractures (800–829), muscu-
loskeletal and connective tissues disease (710–739), or sickle cell
anemia (282.6x) 6 months before index date were excluded.
Likelihood of a migraine ED visit during the 12 months after
index date was estimated using logistic regression while con-
trolling for age, gender, race, metropolitan status of county of
residence, physician supply in county, butalbital and narcotic
medication use 6 months before index date. RESULTS: Data
from 43,791 subjects were analyzed. Mean age was 31 years (SD
= 17), 23% were male and 55% were Caucasians. Six percent
of subjects had used butalbitals and 28% had used narcotics 6
months before index date, and 3% subjects had at least one
migraine ED visit 12 months after index date. Females, non-Cau-
casians, residents of metro counties or counties that had lower
than average physician per 10,000 population ratio were more
likely to have an ED visit (adjusted odds ratio, AOR = 1.68, 1.51,
2.37, and 3.10 respectively, p < 0.05). Prior narcotic use signif-
icantly increased the risk of ED visit (AOR = 1.82, p < 0.001).
Age and butalbital use had no effect on ED use. CONCLUSION:
Local physician shortage and easy ED access encouraged ED use
for non-urgent medical problems. Improving access to primary
care facilities is crucial for reducing non-urgent ED use.
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OBJECTIVES: To develop a migraine quality of care measure-
ment set at the health plan level, in order to begin measuring and
improving migraine care processes and outcomes. METHODS:
The measurement set was developed through: 1) review of
migraine care guidelines; 2) literature review of quality mea-
surement for migraine care; 3) telephone interviews with thought
leaders in migraine care and quality improvement; and 4) assem-
bly of a national advisory board consisting of prominent leaders
within migraine care, quality measurement and managed care.
The advisory board reviewed collected information from tasks
1–3, discussed candidate measures, and established a consensus
on target measures to be included in the set. RESULTS: The advi-
sory board selected 19 potential measures that could be imple-
mented at the health plan level using administrative (claims)
data. These measures capture information on: migraine diagno-
sis and prevalence; use of preventive and therapeutic medica-
tions; and, primary care, specialist, emergency, diagnostic
radiologic, and inpatient service utilization. The measurement
speciﬁcations have been developed to mirror technical speciﬁca-
tions for administrative measures in the Health Plan Employer
Data and Information Set (HEDIS). CONCLUSION: Develop-
ment of an evidence-based set of quality measures for migraine
care is an important advance in seeking to measure and improve
care for migraineurs. Despite its prevalence, and impact on direct
and indirect costs, migraine is not currently being addressed in
the national quality measurement movement. The measurement
set is now being pilot tested in health plans to assess feasibility
of data collection, properties of the measures, and correlation
among the measures.
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OBJECTIVES: Patient knowledge is associated with their ability
to manage their disease (self-efﬁcacy). The objective of this study
was to examine the extent to which patients with systemic lupus
erythematosus (SLE) reported speciﬁc organs/system involvement
that was consistent with medical records. METHODS: In a cross-
sectional study, patients with SLE were asked to indicate whether
the following organ systems were affected by their lupus:
skin/hair/scalp, joints, kidneys, brain, heart/lungs, (abnormal)
blood counts, blood clots (including stroke). A retrospective chart
review was undertaken to examine organ involvement and tests
as recorded by their physician. Exact and kappa measures of
agreement between physician and patient report were calculated
for each organ system. RESULTS: The patient sample (n = 70)
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had a mean (SD) age of 43.0 (13.4) and was 95.7% female. Exact
agreement between organ involvement ranged from 47.8% for
blood counts to 86.6% for blood clots. There was signiﬁcant
agreement for involvement of skin/hair/scalp (K = 0.46), kidneys
(K = 0.55), brain (K = 0.54), and blood clots (K = 0.60). Poor
agreement was noted for abnormal blood counts (K = 0.08) and
joint involvement (K = 0.06). CONCLUSION: Similar to studies
of patient-physician agreement on quality of life, stronger agree-
ment between patient and physician assessment was reported for
more physical manifestations of disease. Results suggest there is
opportunity to improve patient management through education
and patient-provider communication.
PND21
PRODUCT ENHANCEMENTS DECREASE THE INCIDENCE OF
INJECTION SITE REACTIONS AND PAIN RESULTING IN
IMPROVED ADHERENCE TO THERAPY IN PATIENTS WITH
MULTIPLE SCLEROSIS
Scanzillo J1, Bennett R1, Biancucci P1, Divan V2, Sherman S1,AL-
Sabbagh A3
1Serono, Inc, Rockland, MA, USA, 2Pﬁzer, New York, NY, USA, 3Serono,
Rockland, MA, USA
OBJECTIVES: To evaluate the impact of product enhancements
such as a new autoinjector (Rebiject II) and ﬁner needles upon
adherence to therapy for patients receiving subcutaneous (sc) Inter-
feron-beta-1a (IFNB-1a) 44 mcg tiw. Injection site reactions (ISRs)
are a common cause of treatment discontinuation in patients with
multiple sclerosis (MS). Support organizations such as the MS Life-
Lines program may help patients manage ISRs, however, simpliﬁ-
cation of the injection process via autoinjectors and ﬁner gauge
needles may also help to decrease ISRs. METHODS: Data were
gathered by the MS LifeLines program between August 2003 and
November 2004 (before product enhancements) and again
between December 2004 and March 2006 (after product enhance-
ments). Patients were contacted by nurse educators at regular inter-
vals and asked a series of questions to determine whether they were
adherent to therapy or had discontinued, and, if they had discon-
tinued, why they had done so. Reasons for discontinuation were
recorded and divided into 3 categories: ISRs, pain and/or burning
at the injection site, or other reasons. RESULTS: Between August
2003 and November 2004, 11,783 total patients received subcu-
taneous (sc) IFNB-1a 44 mcg tiw. Of the 2079 patients who dis-
continued therapy 190 (9.1%) were due to ISRs and 175 (8.4%)
were due to pain and/or burning at the injection site. Between
December 2004 and March 2006, when Rebiject II and ﬁner gauge
needles were incorporated, 12,968 total patients received sc IFNB-
1a 44 mcg tiw. Of the 1780 (13.7%) who discontinued therapy 99
(5.6%) were due to ISRs and 33 (1.9%) were due to pain and/or
burning at the injection site. CONCLUSION: These results demon-
strate that product enhancements have dramatically decreased dis-
continuation of therapy due to overall ISRs and injection pain or
burning in patients administering (sc) IFNB-1a 44 mcg tiw. The
decreased discontinuation to therapy may potentially improve
long-term outcomes.
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OBJECTIVES: To examine differences in the prevalence of other
diseases for patients with and without Alzheimer’s Disease (AD),
and the independent effect of AD on cost, beyond the expected
cost of treating other medical conditions. METHODS: We used
MarketScan Medicare Supplemental and Coordination of Bene-
ﬁts claims data, 2003–2004, for over-age-65 individuals with
Medicare and employer-sponsored plans including drug beneﬁts.
We identiﬁed AD patients by an AD diagnosis or an exclusively
prescribed AD medication in 2003, and selected a demographi-
cally-matched, non-demented Control (3 : 1 ratio to AD). Apply-
ing Diagnostic Cost Groups (DCGs), a comprehensive disease
classiﬁcation and prediction system, we calculated a prospective
relative risk score (RRS) that predicts 2004 costs from non-AD
illnesses in 2003; the mean RRS of all individuals enrolled for
all of 2003 and ≥1 month in 2004 was set to 1.00. We used
regression to estimate AD’s independent effect on cost overall
and among patients with selected non-AD conditions. RESULTS:
The AD Cohort (n = 25,109) is sicker (mean RRS 1.23 vs. 1.04)
than the Controls (n = 75,327); they have more comorbidities
(mean of 8.1 unique medical conditions vs. 6.5) and 34% higher
costs ($13,936 vs. $10,369). However, excess annual costs
attributable to AD are estimated to be only $2307, with outpa-
tient pharmacy being the key driver ($1711 in excess costs). The
AD Cohort has more diabetes, heart, mental health, injuries, vas-
cular, and urinary problems. For patients with certain comor-
bidities (such as, anxiety disorders), excess costs attributable to
AD reach $6000. CONCLUSION: AD patients are sicker than
demographically similar patients, yet cost even more than is
accounted for by their excess morbidity. Much of the additional
cost is due to greater use of outpatient pharmaceuticals.
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OBJECTIVES: To compare the psychometric properties of
migraine speciﬁc health related quality of life instruments based
on McHorney and Tarlov (1995). METHODS: Eleven instru-
ments were identiﬁed based on the following criteria: at least one
peer reviewed publication of the instrument; instrument focus on
HRQOL; psychometric data and instrument availability. Identi-
ﬁed instruments were evaluated based on the McHorney and
Tarlov’s (1995) criteria for individual decision making and
included: item information; administration time (practicality);
instrument breadth; depth (ﬂoor and ceiling effects <15%); 
reliability (internal consistency and test-retest) and validity.
RESULTS: Five migraine speciﬁc health related quality of life
Instruments were identiﬁed: the Migraine Speciﬁc Quality of Life
Questionnaire (MSQ); Migraine Disability Assessment Score
(MIDAS); 24 hr Migraine Speciﬁc Quality of Life Questionnaire
(MQoLQ); Migraine Speciﬁc Quality of Life Measure (MSQOL)
and the Headache Impact Test-6 (HIT-6). Ideal psychometric
properties were not shown by any of the ﬁve instruments evalu-
ated based on study criteria. This was in part due to lacking 
psychometric data in addition to failure to meet study criteria.
For example, MSQ was the only questionnaire available with
reported depth and internal consistency data. MSQ, MIDAS,
MQoLQ were the most frequently used questionnaires. MSQ
was notable for the most extensive psychometric data to support
the scale including adequate item information, breadth, depth
(ﬂoor and ceiling effects <10%) and validity (multitrait-multi-
method, convergent, known groups and conﬁrmatory factor
analysis). Although internal consistency for all the dimensions of
MSQ (α = 0.86–0.96) was adequate for group level decision
